Stockscreener 앱 받기
560.85
3.86%
20.85
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research
Is Povetacicept The Next Chapter For Vertex Pharmaceuticals (NASDAQ:VRTX)? - Kalkine Media
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool
Vertex Pharmaceuticals (VRTX) CEO Jeff Leiden's Leadership Journ - GuruFocus
Scotiabank keeps USD 558.00 target for Vertex Pharma stock - ad-hoc-news.de
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - TradingView
Vertex Pharmaceuticals advances povetacicept: what it means for Vertex Pharmaceuticals stock - ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
BHC Q3 Earnings Preview: Here's What You Should Know - Zacks Investment Research
Vertex Pharmaceuticals shares may move 4.3% on earnings By Investing.com - Investing.com South Africa
The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2 - 24/7 Wall St.
Vertex Pharmaceuticals shares may move 4.3% on earnings - Investing.com
Vertex Pharmaceuticals shares may move 4.3% on earnings By Investing.com - Investing.com UK
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Vertex Pharma publishes kidney results as Vertex Pharma stock trades at EUR 469.45 - ad-hoc-news.de
I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move - The Motley Fool
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. - The Motley Fool
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. - The Motley Fool
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026Slideshow (NASDAQ:VRTX) 2026-10-23 - Seeking Alpha
Vertex reports positive IgAN trial data, FDA decision due Nov. 30 - Investing.com Australia
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead? - Trefis
Cystic Fibrosis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - StreetInsider
Vertex Pharmaceuticals Incorporated Estimates – LSE:0QZU - TradingView
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Form 4 Vertex Pharmaceuticals Inc: Daniel J. Brennan (Director) For: 20 October - Investing.com UK
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
VERTEX PHARMACEUTICALS INC / MA Initial Statement of Beneficial Ownership - Stock Titan
Vertex Pharmaceuticals Inc. Research & Ratings | VRTX - Barron's
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Vertex Pharma stock at EUR 464.48 ahead of the Xetra open: biotech group - AD HOC NEWS
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors? - Yahoo Finance
Vertex Pharma stock: Third-quarter results arrive November 2 for Vertex Pharma stock - AD HOC NEWS
Vertex appoints Daniel Brennan. Vertex Pharma stock has USD 130.4 billion value - AD HOC NEWS
Vertex Pharma stock pre-market at EUR 456.53 ahead of Xetra open - AD HOC NEWS
Vertex Appoints Daniel Brennan to its Board of Directors - BioSpace
Vertex Pharmaceuticals (VRTX) Expands Board to Eleven Members wi - GuruFocus
Why Should You Think About Vertex Differently Now? - Yahoo Finance
Form 8K Vertex Pharmaceuticals Inc For: 20 October By Investing.com - Investing.com Nigeria
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals appoints Daniel Brennan to board of directors - Investing.com
Vertex Pharmaceuticals appoints Daniel Brennan to board, joins Audit and Finance Committee - TradingView
13.62%
자본화:
|
볼륨(24시간):